Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Vasculitis 1Neoplasms 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Glomerulonephritis 1Colorectal Neoplasms 1Colonic Neoplasms 1COVID-19 1Adenomatous Polyposis Coli 1

Interventions

Standard of Care 8Hydroxychloroquine 4BNT162 Vaccine 4Practice Guidelines as Topic 3Blood Specimen Collection 32019-nCoV Vaccine mRNA-1273 3tocilizumab 2sotrovimab 2cilgavimab and tixagevimab drug combination 2Specimen Handling 2Sodium Chloride 2CVnCoV COVID-19 vaccine 2COVID-19 Vaccines 2COH04S1 COVID-19 vaccine 2Azithromycin 2sinovac COVID-19 vaccine 1selinexor 1remdesivir 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1crexavibart 1ciclesonide 1bemcentinib 1avdoralimab 1acalabrutinib 1XAV-19 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × COVID-19 × Niclosamide × Clear all
NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡